ATG5 and head and neck squamous cell carcinoma: Based on this result, we performed drug therapy response prediction of high and low ATG5 expression in transcriptome of HNSCC samples, and found that the IC50 of G2M checkpoint inhibitors were lower in ATG5 high expression HNSCC samples (p < 0.05, Figures 7B–G), which showed a high sensitivity to G2M checkpoint inhibitors.